Cagrilintide research: studies, doses and safety

• Weeks 1-2, phase 2 higher-dose paths: The 1.2 mg, 2.4 mg and 4.5 mg target groups began at 0.6 mg weekly in the phase 2 trial.
• Weeks 3-4, phase 2 higher-dose paths: Those phase 2 groups moved to 1.2 mg weekly after two weeks.
• Weeks 5-6, phase 2 higher-dose paths: The phase 2 groups targeting 2.4 mg or 4.5 mg moved to 2.4 mg weekly.
• Week 7 onward, phase 2 highest-dose path: The phase 2 group targeting 4.5 mg reached that weekly dose after six weeks.
• Week 26: The phase 2 trial estimated 6.0-10.8% average weight loss if treatment was followed versus 3.0% with placebo, with nausea common.

The phase 2 obesity trial used weekly injections for 26 weeks, then six weeks of follow-up without treatment.

27 unique registered studies with cagrilintide-alone or comparator arms; includes ongoing/unreported trials. Reviews and animal studies are not counted.

Key studies

• First human single-dose study: Status: completed. No clinical benefit is established by registration. (source)
• First repeat-dose study: Status: completed. No clinical benefit is established by registration. (source)
• Japanese and White adults: PK: Status: completed. No clinical benefit is established by registration. (source)
• Phase 2: five weekly doses: All five cagrilintide doses reduced weight more than placebo. (source)
• Birth-control pill interaction: Status: completed. No clinical benefit is established by registration. (source)
• Single dose: kidney impairment: A single dose showed no clinically relevant kidney-related exposure change. (source)